Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC cut its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 41.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,161 shares of the medical equipment provider's stock after selling 2,890 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Intuitive Surgical were worth $2,172,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Vanguard Group Inc. raised its position in shares of Intuitive Surgical by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock worth $16,813,478,000 after purchasing an additional 360,591 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Intuitive Surgical by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock worth $4,039,200,000 after buying an additional 243,802 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Intuitive Surgical by 1.8% during the fourth quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider's stock valued at $2,541,356,000 after buying an additional 86,488 shares during the last quarter. Norges Bank purchased a new position in Intuitive Surgical in the 4th quarter worth approximately $2,401,493,000. Finally, Invesco Ltd. lifted its position in Intuitive Surgical by 7.7% in the 4th quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock valued at $2,165,184,000 after acquiring an additional 295,025 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 269 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $590.00, for a total value of $158,710.00. Following the completion of the sale, the chief financial officer now owns 3,282 shares of the company's stock, valued at approximately $1,936,380. This trade represents a 7.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the sale, the director now owns 6,371 shares of the company's stock, valued at $3,312,920. This trade represents a 27.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 33,313 shares of company stock valued at $17,229,143. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Price Performance

Shares of ISRG stock traded down $1.61 during mid-day trading on Friday, hitting $536.55. The stock had a trading volume of 925,598 shares, compared to its average volume of 1,628,568. Intuitive Surgical, Inc. has a 12-month low of $379.67 and a 12-month high of $616.00. The firm's 50-day moving average is $501.36 and its two-hundred day moving average is $534.58. The firm has a market capitalization of $192.31 billion, a P/E ratio of 83.71, a price-to-earnings-growth ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same period last year, the firm earned $1.50 earnings per share. Analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ISRG shares. Royal Bank of Canada decreased their price target on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Bernstein Bank upped their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an "overweight" rating in a research note on Monday, January 27th. Erste Group Bank lowered shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research note on Monday, March 17th. Jefferies Financial Group increased their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Finally, Truist Financial cut their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus target price of $598.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.